Six months after divesting the last remnant of its former identity, LifeMD reported both the largest quarterly subscriber gain in company history and an $8.9 million net loss. The telehealth operator is building faster than it is earning, and the distance between those two trajectories — multi-vertical ambition on one side, deepening quarterly losses on the other — is where this story unfolds.
On November 4, 2025, LifeMD Inc. signed the papers that would make it a pure-play telehealth company. The asset it sold was WorkSimpli, a digital document-services business that had nothing to do with virtual healthcare but everything to do with where the company came from. The buyer was an undisclosed private party. The transaction closed quietly. And with it, the last trace of a corporate identity stretching back more than three decades disappeared from the balance sheet.
The company that now calls itself LifeMD began in 1994 as Conversion Labs, Inc. For most of its existence, it occupied the unglamorous terrain of direct-to-consumer e-commerce: selling supplements, skincare, and digital products through a portfolio of web properties that changed shape with each passing trend. It went public on the NASDAQ on January 29, 2008, a time when telehealth as an industry barely existed. The name change to LifeMD came in February 2021, a rebranding that signaled where management wanted to go but did not yet reflect where the company actually was. WorkSimpli, along with several legacy brands, remained on the books, generating revenue that padded the top line but did nothing to clarify the thesis.
The divestiture changed that arithmetic. By removing WorkSimpli, LifeMD stripped away what management had come to see as a distraction: a non-core asset that muddied the investment narrative and consumed operational attention. What remained was a telehealth platform built around a 50-state affiliated medical group, a portfolio of condition-specific brands, and an increasingly integrated operational backbone. The company emerged from the transaction narrower in revenue but far sharper in purpose.
Schreiber delivered that line on the Q1 2026 earnings call in early May, six months after the WorkSimpli sale. By then, the numbers were beginning to reflect what the structural change implied. The company had just added 42,000 net new telehealth subscribers, the largest quarterly gain it had ever recorded. Revenue came in at $50.2 million, slightly ahead of internal guidance, even though it was essentially flat against the prior-year period that still included a quarter of WorkSimpli contributions. The growth was organic, telemedicine-driven, and accelerating.
The company that reported 42,000 net subscriber additions in Q1 2026 no longer exists in any corporate registry as the entity that went public in 2008.
Yet the clean break also exposed something that the legacy revenue had helped obscure: the cost of the all-in bet. Stripped of its non-core earnings, LifeMD was now a company whose growth story was clear and whose path to profitability was not. The subscriber surge was real, but so was the fact that net losses had widened to $8.9 million in the quarter, up from $1.5 million just three months earlier. The shedding was complete. What came next would test whether the company could build a platform faster than it burned through cash.
Justin Schreiber is the architect. He holds the dual role of Chairman and Chief Executive Officer, and on earnings calls, he speaks in the register of a founder who has been thinking about the same problem for a very long time. The problem, as he frames it, is that most telehealth companies are narrow. They target one condition, one demographic, one recurring prescription. His answer is a platform designed to capture the patient at the virtual front door and route them through a growing number of clinical verticals: men's health, women's health, weight management, cardiology, and whatever comes next, all supported by a common infrastructure that the company owns.
The word "platform" is deliberate. It distinguishes LifeMD from competitors that Schreiber would describe as single-condition telehealth providers: companies that built a brand around one drug class or one patient population and stopped there. LifeMD's thesis is that the economics of virtual care improve when the same patient can be treated for multiple conditions across multiple visits, with prescriptions dispensed through a pharmacy the company controls and, increasingly, reimbursed by insurance rather than paid out of pocket.
That sentence, delivered on the same May 2026 call, functions as a checklist. The medical group, the pharmacy, the labs, the insurance relationships, the pharma partnerships: each represents a piece of infrastructure that LifeMD did not possess in its earlier iterations. Schreiber's argument is that the pieces are now in place and beginning to interact. The counterargument is that assembling a platform and operating one profitably are not the same exercise.
The financial leadership has turned over alongside the strategy. Marc Benathen served as CFO through the end of 2025, guiding the company through the WorkSimpli divestiture and the early stages of the women's health build-out. In early 2026, Atul Kavthekar stepped into the role, arriving at a moment when subscriber growth was accelerating and infrastructure spending was climbing. His presence on the Q1 2026 call brought a measured, numbers-first cadence, a tonal counterweight to Schreiber's platform vision.
The platform Schreiber describes is not a slide deck. Each vertical he references has either launched, beta-tested, or begun processing real patients in the past twelve months. The pace of the build-out has been aggressive by any standard, and the clinical partnerships underpinning it suggest a deliberate effort to acquire credibility rather than simply bolt on new offerings.
The women's health vertical, launched in late 2025, illustrates the approach. LifeMD acquired Optimal Human Health, a practice built around bone health and hormonal medicine, and brought on two clinicians whose reputations extend well beyond the telehealth industry. Dr. Tara Scott is an internationally recognized OB/GYN and functional medicine physician known widely as the "Hormone Guru," a designation that carries weight with the perimenopausal and menopausal patient population LifeMD is targeting. Dr. Doug Lucas is a former orthopedic surgeon who specialized in bone health and built a substantial social media following translating clinical research for a lay audience. Both lend the vertical a clinical authority that a generic telemedicine landing page would lack.
The weight management business has moved with similar speed. In early 2026, LifeMD launched oral Wegovy through a collaboration with Novo Nordisk, the Danish pharmaceutical giant that manufactures the drug. The oral formulation, a once-daily tablet, represents an alternative to the injectable GLP-1 medications that have dominated the obesity market. In parallel, during Q1 2026, LifeMD integrated its RexMD brand with NovoCare, Novo Nordisk's patient support platform, making both injectable and oral Wegovy available to the existing RexMD patient base. The move positioned LifeMD as a dual-channel distributor for what is arguably the most commercially significant drug class of the decade.
Cardiology followed. In Q1 2026, LifeMD beta-launched a virtual cardiology offering across 30 states. The service is earlier-stage than the women's health or weight management verticals, and management has disclosed fewer details about clinical partners or volume. But the direction is consistent: each new vertical extends the platform thesis, adding another reason for an existing patient to stay within the LifeMD ecosystem and another entry point for a new one.
The pieces Schreiber describes — medical group, pharmacy, labs, insurance, pharma partnerships — are now live; the question is whether their interaction produces margins or merely complexity.
Underpinning all of this is the 503-A compounding pharmacy, which began processing prescriptions in Q1 2026 and is now fully licensed to dispense personalized compounded medications in all 50 states. The significance is operational as much as strategic. A telehealth company that relies on third-party pharmacies surrenders a portion of its margin and a measure of its quality control at the point where the clinical encounter becomes a physical product. Owning the pharmacy, particularly one capable of compounding personalized formulations rather than dispensing off-the-shelf products, gives LifeMD a lever that most telehealth peers do not possess. It also adds fixed costs, regulatory complexity, and the kind of operating risk that a software-only competitor never has to manage.
Taken together, the vertical build-out represents an unusual breadth for a company of LifeMD's size. At roughly $200 million in annualized revenue, the company now operates across men's health, women's health, weight management, and cardiology, with an owned pharmacy and expanding insurance relationships. That is a scope more commonly associated with larger, better-capitalized competitors. Whether LifeMD can support that scope on its current revenue base is the central financial question.
The Q1 2026 numbers tell two stories that sit uncomfortably alongside each other. The first is a story of accelerating demand. The second is a story of deepening cost. Neither cancels the other out.
| Metric | Q1 2026 | Q4 2025 | YoY Change |
|---|---|---|---|
| Revenue | $50.2M | — | ~flat ($50.9M) |
| Gross Margin | 84.8% | 81.8% | +420 bps |
| Active Subscribers | ~365,000 | — | +26% |
| Net Subscriber Additions | 42,000 | — | Largest in company history |
| Net Loss | ($8.9M) | ($1.5M) | — |
| Free Cash Flow | $0.34M | ($3.44M) | — |
Source: LifeMD Q1 2026 earnings call and press release, May 6, 2026
Revenue of $50.2 million landed above the company's guidance range of $48 million to $49 million, but it was essentially flat against the $50.9 million reported in the prior-year quarter. The flat comparison is partly structural: the year-ago quarter included a partial contribution from WorkSimpli, which was still on the books. But the result nonetheless underscores a truth about the current business: subscriber growth is the engine, and it needs to keep firing at elevated rates to produce the top-line acceleration that the full-year guidance implies.
The subscriber number is the headline. LifeMD ended Q1 2026 with approximately 365,000 active telehealth subscribers, up 26 percent from the prior year. The 42,000 net additions in the quarter were the largest in company history. Recurring subscriptions now account for nearly all of revenue. Kavthekar's phrasing on the call was careful and precise, which means the revenue base is increasingly predictable even as the growth trajectory remains steep. In a subscription business, that combination is generally valuable.
Gross margin tells a genuine efficiency story. At 84.8 percent, it expanded roughly 420 basis points year-over-year and 300 basis points sequentially from 81.8 percent in Q4 2025. Management attributed the improvement to lower shipping and fulfillment costs, a line item that matters more for a company dispensing physical medications than for a pure software telehealth business. The in-house pharmacy, still in its early stages, is designed to push that margin higher over time by capturing the economics that would otherwise flow to third-party fulfillment partners.
Then the picture shifts. Net loss in Q1 2026 was $8.9 million, a figure that widened sharply from $1.5 million in Q4 2025 and from $2.1 million in Q2 2025. The sequential deterioration is not subtle. Management attributes the increase to stepped-up marketing investment, where customer acquisition costs are front-loaded against subscriber relationships expected to generate revenue over multiple quarters, plus the infrastructure spending required to stand up the pharmacy, the new verticals, and the insurance integration. The argument is that these are investment losses, not structural ones.
A record quarter for subscriber growth was also the least profitable quarter in over a year.
Free cash flow offers a modest counterpoint. At $0.34 million in Q1 2026, it swung from negative $3.44 million in Q4 2025, suggesting that the cash demands of the business, while significant, are not uniformly worsening. The trailing twelve-month picture remains uneven, and a single quarter of marginally positive free cash flow does not establish a trend. But it does indicate that the gap between GAAP losses and cash consumption is worth watching, particularly if gross margins continue to improve and subscriber acquisition costs begin to moderate as insurance coverage expands.
The financial picture, in sum, is a company spending to build a platform at the same moment it is proving that demand for that platform exists. Whether the spending peaks before the demand does is the question embedded in every line of the income statement.
LifeMD's management has laid out a series of milestones for the remainder of 2026 that are meant to close the gap between the platform vision and the financial reality. Each milestone addresses a specific constraint: customer acquisition cost, addressable market, reimbursement structure. Together, they form a thesis about how the second half of the year is supposed to look different from the first.
The most consequential near-term event is the expected expansion of insurance coverage to approximately 230 million covered lives, scheduled for May 2026. For a telehealth company that has historically relied on cash-pay patients, individuals paying out of pocket for consultations and prescriptions, the shift toward insurance reimbursement changes the economic model in two ways. First, it reduces the effective cost to the patient, which should widen the top of the funnel and improve conversion rates. Second, it introduces a third-party payer into the transaction, which brings administrative complexity but also the potential for contracted, recurring revenue streams. Schreiber has framed insurance coverage as a lever for lowering customer acquisition costs, which would directly address the marketing spend that drove the Q1 loss expansion.
July 1, 2026, brings the scheduled launch of the Medicare GLP-1 bridge program. The program targets a specific regulatory window: Medicare does not currently cover GLP-1 medications for weight loss alone, but legislative momentum toward coverage has been building. A bridge program would provide qualifying Medicare patients with access to GLP-1 therapies during the gap period, positioning LifeMD to capture a demographic that is both clinically appropriate for GLP-1 treatment and largely untapped by cash-pay telehealth models. The details of the program, including pricing, clinical criteria, and volume expectations, have not been publicly disclosed in full, but the launch date signals that the operational work is underway.
Management reaffirmed full-year 2026 guidance on the Q1 call: revenue of $220 million to $230 million and adjusted EBITDA of $12 million to $17 million. At the midpoint, that implies roughly $175 million to $180 million in revenue over the final three quarters, a significant ramp from the $50.2 million run rate reported in Q1.
The Q4 exit rate Schreiber describes, above $250 million in annualized revenue and above $25 million in adjusted EBITDA, represents a margin structure that the company has not yet demonstrated at any point in its public history. Getting there requires not just continued subscriber growth but a meaningful inflection in the relationship between revenue and costs. The insurance expansion, the Medicare bridge program, the pharmacy ramp, and the maturing of new verticals are all supposed to contribute. None is guaranteed to deliver on the timeline management has set.
Justin Schreiber has spent the past eighteen months transforming a company with a thirty-year history into something that barely resembles its former self. The WorkSimpli divestiture removed the last distraction. The vertical build-out across women's health, weight management, and cardiology gave the platform thesis substance. The subscriber numbers proved that patients are willing to walk through the virtual front door. What the Q1 2026 financials made clear is that the door is expensive to keep open. The $8.9 million quarterly loss is either the cost of building a durable platform ahead of the competition or evidence that the platform, however ambitious, cannot yet pay for itself. The milestones ahead — insurance, Medicare, the pharmacy ramp — will determine which interpretation holds.